Wiewrodt et al. [22] showed that patients expressing ≤30 fmolmg-1 MGMT protein in the pretreatment tumor volume had a significantly better response to alkylating therapy than those with MGMT protein above this level. This evidence concerns the gene MGMT and neoplasm.